Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 231 - 240 of 400

Selected Filters:
18 November 2022

Self-reported and Pill Count Measures of Adherence to Oral HIV PrEP among Female Sex Workers Living in South-Western Uganda

This article from PLOS One reports on a study evaluating PrEP adherence amongst female sex workers in southwestern Uganda using clinic-based pill counts and self-reported measures, and examines factors associated with protective levels of adherence.

Research, Service Delivery

External Link
18 November 2022

Transgender Women in HPTN 083: An evaluation of safety, efficacy, and gender affirming hormonal therapy interactions with long-acting cabotegravir

This poster from AIDS 2022 presents an analysis of results from the HPTN 083 study, looking at the impact of feminizing gender affirming hormones on cabotegravir (CAB) for PrEP pharmacokinetics.

Research

Document
17 November 2022

Initial Implementation of HIV PrEP for People who are Incarcerated in Zambia: A cross-sectional observational study

This article from The Lancet HIV describes a cross-sectional observational study of a PrEP programme implemented between October 2020 and March 2021 in 16 criminal justice facilities in four Zambian provinces.

Research, Service Delivery

External Link
17 November 2022

Prevalence of HIV PrEP Prescribing Among Persons With Commercial Insurance and Likely Injection Drug Use

This article from the Journal of the American Medical Association (JAMA) estimates HIV PrEP uptake among commercially insured persons with opioid or stimulant use disorder by injection drug use status in the USA.

Research, Service Delivery

External Link
15 November 2022

Results from a Safety Study of the Dapivirine Vaginal Ring and Oral PrEP in Breastfeeding Mother-Infant Pairs

This poster from AIDS 2022 presents results from the MTN-043/B-Protected trial, comparing the safety profile of the dapivirine vaginal ring against oral PrEP use during breastfeeding.

Research

Document
14 November 2022

Uptake and Use of Oral PrEP among Heterosexual Men: Results and lessons from a pilot study in Johannesburg, South Africa

Although most PrEP strategies and programs have focused on other populations, formative research conducted by the Mpilo Project in South Africa found that PrEP may also be beneficial and appealing to a substantial segment of heterosexual men. From August 2021 to July 2022 the project implemented a pilot study providing PrEP to 564 men, free…

Research, Service Delivery

Event
11 November 2022

PMM Landscape Analysis, Malawi & Zimbabwe (2020)

PMM is advancing planning for future biomedical prevention product introductions, with a focus on CAB-LA, to avoid oral PrEP challenges and reduce time to impact. PMM used quantitative and qualitative methods to identify sub-national geographies, target populations, delivery channels, and prevention networks to prioritize in early introduction activities for CAB-LA.

Research, Service Delivery

Document
11 November 2022

The Global Men and HIV Technical Working Group (MENHT) Webinar Series -Episode #5 – Men and PrEP

Global data shows that men living with HIV, in all their diversity, are less likely than women to know their HIV status, less likely to initiate ART, less likely to remain engaged in care, and less likely to be virally suppressed. Oral PrEP is recommended under one of the five key HIV prevention pillars and…

Demand Creation/Marketing, Research

Event
10 November 2022

Relative Cost-effectiveness of Long-acting Injectable Cabotegravir versus Oral Pre-exposure Prophylaxis in South Africa based on the HPTN 083 and HPTN 084 Trials: A modelled economic evaluation and threshold analysis

This article from The Lancet HIV estimates the incremental cost-effectiveness of long-acting injectable cabotegravir (CAB for PrEP) compared with tenofovir disoproxil fumarate and emtricitabine (TDF/FTC oral PrEP) in South Africa, using methods standard to government planning, and determines the threshold price at which CAB for PrEP is as cost-effective as TDF/FTC oral PrEP.

Financing & Costing, Research

External Link
10 November 2022

Examining Provincial PrEP Coverage and Characterizing PrEP Awareness and Use among Gay, Bisexual and Other Men who Have Sex with Men in Vancouver, Toronto and Montreal, 2017–2020

This article from Journal of the International AIDS Society examines differences over time in PrEP uptake and assessed factors associated with PrEP awareness and use in gay and bisexual men who have sex with men in Montreal, Toronto, and Vancouver, Canada.

Research

External Link